m88 live casino Assisted Nasdaq-listed Legend Biotech in its Follow-on Public Offering

m88 live casino December 20, 2021, the Nasdaq listed company Legend Biotech Corporatim88 live casino (“Legend Biotech” with stock code LEGN), successfully completed its follow-m88 live casino public offering of 8,615,575 American Depositary Shares (“ADSs”), inclusive of the over-allotment, at the price of USD 40 per ADS, raising funds of approximately USD 345 millim88 live casino.

Legend Biotech is a clinical-stage biopharmaceutical company dedicated to developing novel cell therapies for tumors and other indicatim88 live casinos in America, China and Europe. Its flagship product candidate is LCAR-B38M/JNJ-4528 which was jointly developed by Legend Biotech and Janssen Biotech, Inc., a pharmaceutical company cm88 live casinotrolled by Johnsm88 live casino & Johnsm88 live casino. It is a chimeric antigen receptor (CAR) T-cell immunotherapy treatment for multiple myeloma.

In June 2020, m88 live casino assisted Legend Biotech in its initial offering of ADSs and its listing on the Nasdaq Global Select Market. In this project, m88 live casino continued to act as the Chinese legal counsel to Legend Biotech and advised it on its follow-on public offering from the perspective of PRC laws. Specifically, m88 live casino conducted legal due diligence on the Chinese subsidiaries of Legend Biotech, drafted, reviewed, and revised the application and offering documents regarding the follow-on public offering, and issued Chinese legal opinions.

The leading partners of this project wereM88 Game ,合伙人,专业领域,资本市场,私募股权创业投资andM88 Game 关于我们 .